CXCR2 and pancreatic neoplasm: Also, in pancreatic cancer mouse models, CXCR2+CD68+ macrophages (M2 phenotype) are recruited to the TME by tumor-derived CXCL8, where they contribute to local immunosuppression, thereby reducing the effectiveness of PD-1 blockade therapy [157].